½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1446448

½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå - ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Products (Pacemakers (Implantable, External), Defibrillators, Cardiac Resynchronization Therapy), By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 294¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â¿¡ °ÉÃÄ 6.9%ÀÇ À¯¸®ÇÑ CAGR·Î È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ½ÉÇ÷°ü Àå¾ÖÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ ½ÉÀå¹Úµ¿°ü¸® ±â±âÀÇ Ã¤Åà Ȯ´ë°¡ Æ÷ÇԵ˴ϴÙ. ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2021³â 9¿ù ÇöÀç, ¸Å³â ¾à 65¸¸ 9000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÉÀ庴À¸·Î »ç¸ÁÇß½À´Ï´Ù. COVID-19 ÆÒµ¥¹Í½Ã¿¡´Â Çʼö°¡ ¾Æ´Ñ ½ÉÇ÷°ü°è Ä¡·á¸¦ Æ÷ÇÔÇÑ ¼±ÅÃÀû Ä¡·á°¡ ¿¬±âµÇ°Å³ª ÁߴܵǾú±â ¶§¹®¿¡ ½ÃÀåÀº ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù.

¸ÞµåÆ®·Î´Ð, ¾Öº¿, º¸½ºÅÏ »çÀ̾ðƼÇÈ ÄÚÆÛ·¹ÀÌ¼Ç µî ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ½ÉÀå¹Úµ¿°ü¸® »ç¾÷¿¡¼­ ¼¼°èÀûÀ¸·Î °Å¾×ÀÇ ¼Õ½ÇÀ» ÀÔ¾ú½À´Ï´Ù. ±× °á°ú 2020³â ½ÃÀåÀº ¸¶À̳ʽº ¼ºÀåÀÌ µÇ¾ú½À´Ï´Ù. °©ÀÛ½º·± ½ÉÁ¤Áö¿¡ ´ëóÇÏ´Â ¼ö¿ä Áõ°¡´Â ¸ðµç À¯ÇüÀÇ ½ÉÀå¹Úµ¿°ü¸® ±â±âÀÇ ±â¼ú Çõ½ÅÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ½Ä °¡´ÉÇÑ ±â±â¿¡ ´ëÇÑ ±â¼ú Çõ½Å¿¡´Â ÇÇÇÏ ÀåÄ¡ ¹× °æÁ¤¸Æ ÀåÄ¡¿Í °°Àº ȯÀÚÀÇ Æí¾ÈÇÔ ¼öÁØÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Á¦Ç°µµ Æ÷ÇԵ˴ϴÙ. ½º¿þµ§ ±³ÅëûÀº ¹«ÀÎ Ç×°ø±â¸¦ »ç¿ëÇÏ¿© AED¸¦ ¹è´ÞÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ ½ÃÇè ´Ü°è ÇÁ·Î±×·¥À» ½Ç½ÃÇß½À´Ï´Ù. ÀÌ°ÍÀº AEDÀÇ ¹è¼Û ½Ã°£À» ´ÜÃàÇÏ°í ½Å¼ÓÇÑ Ä¡·á·Î »ýÁ¸ °¡´É¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

µû¶ó¼­ ±â¼úÀû Áøº¸ ¹× Á¦Ç° Çõ½ÅÀ¸·Î ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Çõ¸íÀûÀÎ ±â¼ú Áøº¸ÀÇ Â¡ÈÄ´Â ½ÃÀåÀ» ºü¸£°Ô º¯È­½ÃÅ°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È®´ë°¡ À¯¸®ÇÑ °¡´É¼ºÀ» âÃâÇÏ°í ÀÖ½À´Ï´Ù. ´ë±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ßºñ Áõ°¡ ¹× ½ÅÁ¦Ç° Ãâ½Ã°¡ ´õ¿í ¼ºÀåÀ» ÃßÁøÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 10¿ù, Abbot»ç´Â Àεµ¿¡¼­ »õ·Î¿î ICD¿Í CRT-D¸¦ Ãâ½ÃÇÏ¿© ÀÌ ³ª¶ó¿¡¼­ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇß½À´Ï´Ù. ¶ÇÇÑ È¸»ç´Â 2020³â 2¿ù Gallant ICD ¹× CRT-D ÀåÄ¡ÀÇ CE ¸¶Å© ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ±â¾÷Àº ±¤¹üÀ§ÇÑ Á¦Ç°À» Á¦°øÇϱ⠶§¹®¿¡ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.

½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2023³â ½ÃÀå ±Ô¸ð´Â 185¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø±â°£ µ¿¾È CAGR 6.9%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.
  • Á¦Ç°º°·Î´Â Á¦¼¼µ¿±â°¡ ¼¼°è ä¿ë·üÀÇ ³ôÀÌ¿¡¼­ 2023³â¿¡ 39.39% ÀÌ»óÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ü¿Ü½Ä Á¦¼¼µ¿±â ºÐ¾ß¿¡¼­ ÀÚµ¿ ü¿Ü½Ä Á¦¼¼µ¿±â ºÐ¾ß´Â ÆäÀ̽Ì, Áï ½ÉÀå ¼öÃàÀ» ÀÚ±ØÇÏ´Â ÆÞ½º Àü·ù°ø±Þ°ú ºÎÁ¤¸Æ°ú ºó¸ÆÀ» Á¤»ó ½É¹ÚÀ¸·Î º¯È¯ÇÏ´Â Á¦¼¼µ¿°ú °°Àº °ü·Ã ÀÌÁ¡À¸·Î ÀÎÇØ °¡Àå ³ôÀº ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2023³â ºÏ¹Ì´Â ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ½ÉÀå¹Úµ¿°ü¸® ±â±âÀÇ ³ôÀº º¸±Þ·ü·Î ½ÃÀå¿¡¼­ ¾ÐµµÀûÀÎ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï ±¹°¡ÀÇ Á¸Àç·Î ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • Á¦Ç°ÀÇ ½º³À¼¦
  • °æÀï ±¸µµÀÇ ½º³À¼¦

3Àå ½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå : º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­ ¹× ¹üÀ§
  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡
    • Àúħ½À óġ¿¡ ´ëÇÑ ±âÈ£ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ÀåÄ¡¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë
  • ½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®
    • °¡°Ý ºÐ¼®

Á¦4Àå ½ÉÀå¹Úµ¿°ü¸® ±â±â : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Á¦Ç°º° ½ÃÀå Á¡À¯À²(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • Á¦Ç°º° ¼¼°è ½ÉÀå¹Úµ¿°ü¸® ±â±â ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
    • ÆäÀ̽º¸ÞÀÌÄ¿
    • Á¦¼¼µ¿±â
    • CRT

Á¦5Àå Áö¿ªÀÇ ºñÁî´Ï½º ºÐ¼®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ÇöȲ
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • ű¹
    • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîƼ³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦6Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷º° ÃÖ±ÙÀÇ µ¿Çâ ¹× ¿µÇ⠺м®
  • ȸ»ç ¹× °æÀïÀÇ ºÐ·ù
  • º¥´õ »óȲ
    • Physio-Control, Inc.
    • Medtronic, plc
    • ABBOTT
    • Boston Scientific Corporation
    • Schiller
    • Koninklijke Philips NV
    • Biotronik
    • Progetti Srl
    • Zoll Medical Corporation
    • LivaNova Plc
AJY 24.03.21

Cardiac Rhythm Management Devices Market Growth & Trends:

The global cardiac rhythm management devices market size is anticipated to reach USD 29.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 6.9% from 2024 to 2030. The key factors driving the market include growth in the adoption of cardiac rhythm management (CRM) devices owing to the increasing prevalence of cardiovascular disorders. According to the Centers for Disease Control and Prevention (CDC), as of September 2021, approximately 659,000 Americans die suffering from heart disease every year. The market was negatively impacted during the COVID-19 pandemic, as elective procedures, including the non-essential cardiovascular procedures, were postponed or canceled during the pandemic.

Major players in the market such as Medtronic; Abbott; and Boston Scientific Corporation, incurred huge losses in their cardiac rhythm management business segments globally. This resulted in negative growth of the market in 2020. The rising demand for handling sudden cardiac arrests is leading to innovation in all types of cardiac rhythm management devices. Innovation with regards to implantable devices includes products, such as subcutaneous and transvenous devices, that aim to increase the comfort level of patients. Swedish Transport Agency ran a program under the test phase, which aimed to deliver AEDs using a drone. This may reduce the delivery time of an AED, increasing the chances of survival with faster treatment.

Therefore, the market is anticipated to grow because of technological advancements and product innovations. Revolutionary technological signs of progress are rapidly transforming the market. These expansions are producing lucrative potentials. An increase in R&D expenditure and new product launches by leading firms further fueled the growth. For instance, in October 2020, Abbott launched its new ICD and CRT-D in India, hence expanding its product portfolio in the country. The company had also received CE Mark approval for its Gallant ICD and CRT-D devices in February 2020. Such factors boost market growth. Key market players account for a significant share of the market owing to their extensive product offerings.

Cardiac Rhythm Management Devices Market Report Highlights:

  • The market was valued at USD 18.57 billion in 2023 and is expected to expand at a CAGR of 6.9% during the forecast period
  • By product, defibrillators dominated the market with a share of over 39.39% in 2023 due to their high adoption globally
  • In the external defibrillator segment, the automatic external defibrillator segment held the highest revenue share owing to associated benefits, including pacing, i.e., delivering pulses of the current to stimulate heart contraction as well as cardioversion, converting arrhythmia or tachycardia to a normal heartbeat
  • In 2023, North America held the dominant share of the market owing to the rising prevalence of cardiovascular diseases and high adoption of CRM devices
  • Asia Pacific region is expected to show lucrative growth over the forecast period owing to the presence of emerging countries such as China and India

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Cardiac Rhythm Management Devices Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product Snapshots
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cardiac Rhythm Management Devices Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Growing prevalence of cardiovascular disease
    • 3.4.2. Increasing preference for minimally invasive procedures
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost associated with the devices
  • 3.6. Cardiac Rhythm Management Devices Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape
    • 3.6.3. Pricing Analysis

Chapter 4. Cardiac Rhythm Management Devices: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cardiac Rhythm Management Devices Market By Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 For the Following
    • 4.4.1. Pacemakers
      • 4.4.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.1.1.1. Implantable
      • 4.4.1.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.1.1.2. External
      • 4.4.1.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 4.4.2. Defibrillators
      • 4.4.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.1. Implantable Cardioverter Defibrillators (ICD)
      • 4.4.2.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.1.1.1. S-ICD
      • 4.4.2.1.1.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.1.1.2. T-ICD
      • 4.4.2.1.1.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.2. External Defibrillator
      • 4.4.2.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.2.1.1. Manual External Defibrillator
      • 4.4.2.1.2.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.2.1.2. Automatic External Defibrillator
      • 4.4.2.1.2.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.2.1.2.1.3. Wearable Cardioverter Defibrillator
      • 4.4.2.1.2.1.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 4.4.3. Cardiac Resynchronization Therapy (CRT)
      • 4.4.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.3.1.1. CRT-Defibrillator
      • 4.4.3.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 4.4.3.1.2. CRT-Pacemakers
      • 4.4.3.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Framework
      • 5.5.1.4. U.S. Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Canada Market Estimates and Forecasts 2018 To 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Framework
      • 5.6.1.4. UK Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. Germany Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.3. Spain
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. Spain Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.4. France
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. France Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.5. Italy
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Italy Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.6. Denmark
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Denmark Market Estimates and Forecasts 2018 To 2030 (USD Million)
      • 5.6.6.5.
    • 5.6.7. Sweden
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Competitive Scenario
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Sweden Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.6.8. Norway
      • 5.6.8.1. Key Country Dynamics
      • 5.6.8.2. Competitive Scenario
      • 5.6.8.3. Regulatory Framework
      • 5.6.8.4. Norway Market Estimates and Forecasts 2018 To 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Framework
      • 5.7.1.4. Japan Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.7.2. China
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. China Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.7.3. India
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. India Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.7.4. South Korea
      • 5.7.4.1. Key Country Dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory Framework
      • 5.7.4.4. South Korea Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.7.5. Thailand
      • 5.7.5.1. Key Country Dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory Framework
      • 5.7.5.4. Thailand Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.7.6. Australia
      • 5.7.6.1. Key Country Dynamics
      • 5.7.6.2. Competitive Scenario
      • 5.7.6.3. Regulatory Framework
      • 5.7.6.4. Australia Market Estimates and Forecasts 2018 To 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Framework
      • 5.8.1.4. Brazil Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Mexico Cardiac Rhythm Management Devices Market, 2018 - 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. Argentina Market Estimates and Forecasts 2018 To 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. MEA Cardiac Rhythm Management Devices Market, 2018 - 2030 (USD Million)
    • 5.9.2. South Africa
      • 5.9.2.1. Key Country Dynamics
      • 5.9.2.2. Competitive Scenario
      • 5.9.2.3. Regulatory Framework
      • 5.9.2.4. South Africa Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.9.3. Saudi Arabia
      • 5.9.3.1. Key Country Dynamics
      • 5.9.3.2. Competitive Scenario
      • 5.9.3.3. Regulatory Framework
      • 5.9.3.4. Saudi Arabia Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.9.4. UAE
      • 5.9.4.1. Key Country Dynamics
      • 5.9.4.2. Competitive Scenario
      • 5.9.4.3. Regulatory Framework
      • 5.9.4.4. UAE Market Estimates and Forecasts 2018 To 2030 (USD Million)
    • 5.9.5. Kuwait
      • 5.9.5.1. Key Country Dynamics
      • 5.9.5.2. Competitive Scenario
      • 5.9.5.3. Regulatory Framework
      • 5.9.5.4. Kuwait Market Estimates and Forecasts 2018 To 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company /Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of Key Distributors And Channel Partners
    • 6.3.2. Key Customers
    • 6.3.3. Key Company Market Share Analysis, 2023
    • 6.3.4. Physio-Control, Inc.
      • 6.3.4.1. Overview
      • 6.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.4.3. Product Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Medtronic, plc
      • 6.3.5.1. Overview
      • 6.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.5.3. Product Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. ABBOTT
      • 6.3.6.1. Overview
      • 6.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.6.3. Product Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Boston Scientific Corporation
      • 6.3.7.1. Overview
      • 6.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.7.3. Product Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. Schiller
      • 6.3.8.1. Overview
      • 6.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.8.3. Product Benchmarking
      • 6.3.8.4. Strategic Initiatives
    • 6.3.9. Koninklijke Philips N.V
      • 6.3.9.1. Overview
      • 6.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.9.3. Product Benchmarking
      • 6.3.9.4. Strategic Initiatives
    • 6.3.10. Biotronik
      • 6.3.10.1. Overview
      • 6.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.10.3. Product Benchmarking
      • 6.3.10.4. Strategic Initiatives
    • 6.3.11. Progetti Srl
      • 6.3.11.1. Overview
      • 6.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.11.3. Product Benchmarking
      • 6.3.11.4. Strategic Initiatives
    • 6.3.12. Zoll Medical Corporation
      • 6.3.12.1. Overview
      • 6.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.12.3. Product Benchmarking
      • 6.3.12.4. Strategic Initiatives
    • 6.3.13. LivaNova Plc
      • 6.3.13.1. Overview
      • 6.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.3.13.3. Product Benchmarking
      • 6.3.13.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦